A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1802 | Th1196 | Siltuximab | Heavy Chain Sequence Full view | 708 | IIa | Immunological Disorders | Sylvant | Janssen Inc | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents | Interleukin-6 |
| 1819 | Th1210 | Mepolizumab | NA Full view | 0 | Ib | Respiratory Disorder | Nucala | Glaxosmithkline Inc | Lyophilized Powder | Subcutaneous | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors | Interleukin-5 |
| 1843 | Th1231 | Ibritumomab tiuxetan | Heavy chain: QAYLQQS Full view | 652 | IIIc | Cancer | Zevalin | Spectrum Pharmaceuticals B.V. | Colourless Solution | Intravenous | Antibody, Immunosuppressive Agents | B-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |